News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN)'s (JOBS) Recentin Fails Phase 3 Trial, Hurts Shares


3/8/2010 7:03:56 AM

Reuters -- AstraZeneca's cancer drug Recentin failed in a head to head late stage trial with Roche's Avastin in colorectal cancer patients, hurting the Anglo-Swedish drugmaker's shares on Monday. The company said the data, which analysts had expected to be negative for Recentin, showed the experimental drug did not meet its primary endpoint in the Horizon phase III study.

Read at Reuters
Read at Business Week
Read at Guardian
Read at RTT News
Read at Pharma Times [Free Reg Req'd]
Read at Forbes

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES